CCL2 and osteosarcoma: To confirm MMP-3’s involvement in osteosarcoma cell migration and invasion driven by CCL2, we treated osteosarcoma cells with an MMP-3 inhibitor or siRNA, both of which resulted in the inhibition of CCL2-induced enhancement of cell migration and invasion (Figure 3C,D).